Health ministry not to use Itolizumab in clinical protocols for Covid-19

Topics Coronavirus

Biocon, has been manufacturing and marketing Itolizumab under brand name ALZUMAb
The National Task Force on Covid-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said. 

Considering the unmet medical needs in Covid-19, Itolizumab, an already approved drug of Biocon, used for treating psoriasis - a skin condition - was approved for "restricted emergency use" in the treatment of coronavirus by the Drugs Controller General of India (DCGI) recently. 

The permission to market the drug was granted for the treatment of cytokine release syndrome in moderate' to severe' Acute Respiratory Distress Syndrome patients due to Covid-19. "The issue of including the drug in the clinical protocols was discussed in a meeting held on Friday. 

A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for Covid-19," said an official source. 

A domestic biopharmaceutical company, Biocon, has been manufacturing and marketing Itolizumab, a monoclonal antibody, for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013, under the brand name ALZUMAb, the Union health ministry had earlier said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel